the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache

NCT07025187 | Completed

• 1 other identifier: KFSIRB200-612
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the current study is investigating the effect of integrated neuromuscular inhibition technique on adult females with cervicogenic headache. Methods: Forty females with cervicogenic headache will be recruited. Patients will be randomly assigned into two groups, group A and group B . Patients in both groups will receive a traditional medical treatment, but group (B) will receive additional integrated neuromuscular inhibition technique.

Conditions

Cervicogenic Headache

Outcome Measures

Primary Outcomes (1)

• headache pain intensity

  headache pain intensity measured by 11-Numerical rating scale. Primary outcome updated to headache intensity to better reflect the study objective.

  Baseline, 4 weeks and 8 weeks .

Secondary Outcomes (7)

• kinesiophobia

  Baseline, 4 weeks and 8 weeks .

• Isometric endurance capacity of sternocledomastoid and anterior scalene

  Baseline, 4 weeks and 8 weeks .

• the impact of headaches on patients' lives

  Baseline, 4 weeks and 8 weeks .

• neck disability

  Baseline, 4 weeks and 8 weeks .

• headache frequency

  Baseline, 4 weeks and 8 weeks

Study Arms (2)

Control group

OTHER

All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day.

Drug: Muscle relaxants tizanidine

experimental group

EXPERIMENTAL

Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month.

Drug: Muscle relaxants tizanidine; Other: integrated neuromuscular inhibition technique

Interventions

Muscle relaxants tizanidine DRUG

All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day for one month .

Control group; experimental group

integrated neuromuscular inhibition technique OTHER

Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month .

Also known as: INIT

experimental group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• headache intensity ≥ 3 on eleven-point numerical rating scale at enrolment. 4-at least three-month history of headache with a mean frequency of \> 1/week. 5-hypomobility of the upper cervical spine (C0 to C3) on manual examination; and reproduction of the headache on palpation of the upper cervical spine (C0 to C3).
• In addition, patients should exhibit active trigger points within the suboccipital, and upper trapezius muscles, ipsilaterally over the symptomatic side reproducing their headache symptoms .

You may not qualify if:

• Patients will be excluded if they have any of the following:
• cervical radiculopathy,
• history of neck, shoulder trauma or surgery,
• history of intervention for head or neck pain within the previous 3 months,
• A diagnosis of other types of headaches using the criteria of ICHD-3.

Sponsors & Collaborators

• Kafrelsheikh University: lead

Study Sites (1)

Khalid enb elwaleed polyclinic

Tanta, Algharbia, 6620010, Egypt

Location

MeSH Terms

Conditions

Post-Traumatic Headache

Condition Hierarchy (Ancestors)

Headache Disorders, Secondary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of the department

Study Record Dates

• First Submitted: June 9, 2025
• First Posted: June 17, 2025
• Study Start: June 16, 2025
• Primary Completion: November 1, 2025
• Study Completion: November 1, 2025
• Last Updated: November 18, 2025

Record last verified: 2025-11

Locations

EG (1)